Resaphene Suisse AG: FDA approval process for tinnitus therapy tinniwell continues

13.07.2022 - EQS-Media / 13.07.2022 / 12:42 Roggwil, July 13, 2022 - Due to the COVID pandemic, work for the FDA approval of the tinniwell was stopped at the beginning of 2021. This has now been resumed and Chief Medical Officer Thomas Rauterkus has been ...

Related Keywords

United States ,Switzerland ,Roggwil ,Switzerland General ,Thomas Rauterkus ,Elon Musk ,Anke Rauterkus ,Chief Medical Officer Thomas ,Resaphene Suisse ,Chief Executive Officer ,Resaphene Suisse Ag ,